| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
ATOS has been added to the Russell 2000 index, triggering 10-20M+ shares of forced institutional buying by June 25th. Combined with historically exceptional July call open interest (23% of shares outstanding) and short covering pressure, this creates an exceptional gamma squeeze setup with major upside remaining despite an 85% run from $2.90 to $5.35.
ATOS is a biotech with a strong cash position ($138M, no debt), phase-II breast cancer drug in development, and significant potential market cap expansion as it rises above $8.5/share and gains passive index inclusion and retail retail attention. The author believes it combines gamma/short squeeze dynamics with passive buying mechanics similar to previous meme stocks, offering asymmetric upside risk-reward.
End of results.